Support Program for Side Effects and Resources in Cancer Immunotherapy Patients
Tests a navigation program for adults with cancer receiving immunotherapy treatment.
Plain-language title generated from the registry record
Registry title: A Study of a Side Effects and Resource Navigation Program for People With Cancer
Key facts
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 8 sites
Where in United States
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, United StatesTaking people
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)Commack, United StatesTaking people
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, United StatesTaking people
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, United StatesTaking people
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, United StatesTaking people
- City College of New York (Data Collection AND Specimen Analysis)New York, United StatesNot yet recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesTaking people
- Memorial Sloan Kettering Nassau (All Protocol Activities)Rockville Centre, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT07646847
- Record updated
- 28 October 2026
- Original description
The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having participants complete questionnaires.Read full original descriptionShow less
I CARE (Immunotherapy Cutaneous Adverse Events REsearch) - A Trial With Diverse Cancer Patients to Determine the Impact of SDoH and Side Effects Navigation Program on Treatment Continuation
The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having participants complete questionnaires.
Inclusion: Documentation of Disease; o Patient must have pathologically confirmed kidney, bladder, breast, gastrointestinal or lung cancer (per EMR); Prior Treatment; o Within three weeks (+/- 3 weeks) of starting PD-1 or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR); Age ≥ 18 (per EMR); Not Pregnant and Not Nursing (per self-report); At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report); Screens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance orand demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit) (per EMR or self-report); Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report); Can speak English or Spanish (per self-report); Has no serious life-threatening allergies to tape or adhesives (per EMR or self-report); Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team); Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team).